Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS

NEW YORK, September 1, 2017 /PRNewswire/ --

If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.95%; the Dow Jones Industrial Average edged 0.25% higher; and the S&P 500 was up 0.57%. US markets made broad based gains with all sectors finishing the day in green. Pre-market today, DailyStockTracker.com reviews these four Biotechnology stocks: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), Illumina Inc. (NASDAQ: ILMN), and VIVUS Inc. (NASDAQ: VVUS). Access DailyStockTracker.com's free research reports for this morning's stocks line-up at:

http://dailystocktracker.com/register/

Grifols 

Barcelona, Spain headquartered Grifols S.A.'s stock finished Thursday's session 2.48% higher at $20.65. A total volume of 907,380 shares was traded, which was above its three months average of 505.72 thousand shares. The Company's shares have advanced 29.79% in the last twelve months and 28.50% on an YTD basis. The stock is trading above its 200-day moving average by 9.62%. Furthermore, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have a Relative Strength Index (RSI) of 54.52. Free research report on GRFS is available at:

http://dailystocktracker.com/registration/?symbol=GRFS

Halozyme Therapeutics 

Shares in San Diego, California headquartered Halozyme Therapeutics Inc. ended at $13.01, up 2.12% from the last trading session. The stock recorded a trading volume of 881,973 shares. The Company's shares have gained 32.76% in the last twelve months and 31.68% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.49% and 2.24%, respectively. Moreover, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes and other drug candidates in the US, Switzerland, and internationally, have an RSI of 59.39. The complimentary research report on HALO can be downloaded at:

http://dailystocktracker.com/registration/?symbol=HALO

Illumina 

San Diego, California headquartered Illumina Inc.'s stock ended yesterday's session 2.36% higher at $204.46 with a total trading volume of 1.39 million shares, which was above its three months average of 944.27 thousand shares. The Company's shares have advanced 11.25% over the previous three months, 21.46% in the last twelve months, and 59.68% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.50% and 22.88%, respectively. Additionally, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 69.43.

On August 07^th, 2017, research firm Canaccord Genuity upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $170 a share to $215 a share. Visit us today and access our complete research report on ILMN at:

http://dailystocktracker.com/registration/?symbol=ILMN

VIVUS 

On Thursday, shares in Campbell, California headquartered VIVUS Inc. recorded a trading volume of 653,225 shares. The stock finished the day flat at $0.89. The stock is trading below its 50-day moving average by 20.46%. Furthermore, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 22.42. Get free access to your research report on VVUS at:

http://dailystocktracker.com/registration/?symbol=VVUS

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com